AMLX

#1890
Amylyx Pharmaceuticals, Inc. Common Stock
15.17
+1.68%
부문:
베이스:
수익 통화:
일일 변동 비율
15.17
15.17
년간 변동
2.60
17.49
일일 변동
+1.68%
월간 변동
-2.00%
6달 변화
+60.53%
년간 변동율
+384.66%
이전 종가
14.92
Open
15.17
Bid
Ask
Low
15.17
High
15.17
양
174
Open full chart

Financials

Overview 성명 Statistics Dividends
Quarterly Annual
  • Market Capitalization 1.42 B
  • Employee 123
  • Founded 2013
  • CEO N/A
  • Website www.amylyx.com
  • Headquarter Delaware, United States
  • FIGI BBG00DP10YT5
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-0.85
Price to sales ratio
2.95
Dividends per share
—
Dividend yield %
—

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

뉴스